Symptom Duration is not Related to Central Sensitization Inventory in Midportion Achilles Tendinopathy
- PMID: 40322520
- PMCID: PMC12048355
- DOI: 10.26603/001c.134038
Symptom Duration is not Related to Central Sensitization Inventory in Midportion Achilles Tendinopathy
Abstract
Background: There is concern that the prolonged symptom duration commonly observed in Achilles tendinopathy may alter pain processing and lead to development of central sensitization. If true, presence of altered pain processing could explain why nearly one third of individuals with Achilles tendinopathy do not respond to gold standard treatment. Currently, the relationship between symptom duration, symptom severity, pain, and central sensitization in Achilles tendinopathy is unclear.
Purpose: The purpose of this study was assess the proportion of individuals with midportion Achilles tendinopathy who may have central sensitization, as defined by the Central Sensitization Inventory (CSI) part A questionnaire. A secondary aim was to assess the relationship between symptom duration, pain intensity, symptom severity and CSI scores.
Study design: Cross-Sectional Study.
Methods: Individuals diagnosed with midportion Achilles tendinopathy were included (n=182, 57% female (47.3±12.7 years). Bivariate correlations were used to evaluate relationships between symptom duration (time between date of symptom onset and date of study enrollment), symptom severity (assessed by Victorian Institute of Sport Assessment-Achilles, VISA-A), and pain intensity (assessed by Patient-Reported Outcomes Measurement Information System 29, PROMIS-29) with CSI scores.
Results: Nine of 182 individuals (4.9%, 9 females) scored above the clinical cut off for CSI, indicating likely presence of central sensitization. Duration of symptoms did not correlate with CSI score (r = 0.037, 95% CI [-.109, .181] p=0.622). VISA-A had a significant negative correlation with CSI score (r=-0.293, [-.420, -.154] p<0.001), and pain intensity had a significant positive correlation with CSI score (r=0.195, [.051, .331] p=0.008).
Conclusion: Less than five percent of individuals with midportion Achilles tendinopathy met criteria for likely presence of central sensitization as defined by the CSI screening questionnaire. The study findings suggest prolonged symptom duration among those with midportion Achilles tendinopathy is unlikely to increase the occurrence of symptoms associated with central sensitization.
Level of evidence: Level 4.
Keywords: Achilles tendinitis; VISA-A; nociplastic pain; pain intensity.
© The Author(s).
Conflict of interest statement
The authors have no disclosures to report
Figures




Similar articles
-
Injection therapies for Achilles tendinopathy.Cochrane Database Syst Rev. 2015 May 26;2015(5):CD010960. doi: 10.1002/14651858.CD010960.pub2. Cochrane Database Syst Rev. 2015. PMID: 26009861 Free PMC article.
-
Is Platelet-rich Plasma Effective in Treating Achilles Tendinopathy? A Meta-analysis of Randomized Clinical Trials.Clin Orthop Relat Res. 2025 May 1;483(5):779-790. doi: 10.1097/CORR.0000000000003349. Epub 2024 Dec 19. Clin Orthop Relat Res. 2025. PMID: 39745256
-
Evidence of Nervous System Sensitization in Commonly Presenting and Persistent Painful Tendinopathies: A Systematic Review.J Orthop Sports Phys Ther. 2015 Nov;45(11):864-75. doi: 10.2519/jospt.2015.5895. Epub 2015 Sep 21. J Orthop Sports Phys Ther. 2015. PMID: 26390275
-
The Distal Free Achilles Tendon Is Longer in People with Tendinopathy than in Controls: A Retrospective Case-Control Study.Transl Sports Med. 2022 Aug 28;2022:6585980. doi: 10.1155/2022/6585980. eCollection 2022. Transl Sports Med. 2022. PMID: 38655157 Free PMC article.
-
The effect of sample site and collection procedure on identification of SARS-CoV-2 infection.Cochrane Database Syst Rev. 2024 Dec 16;12(12):CD014780. doi: 10.1002/14651858.CD014780. Cochrane Database Syst Rev. 2024. PMID: 39679851 Free PMC article.
References
-
- Clinical risk factors for Achilles tendinopathy: a systematic review. Van Der Vlist A. C., Breda S. J., Oei E. H. G., Verhaar J. A. N., De Vos R. J. 2019Br J Sports Med. 53(21):1352–1361. doi: 10.1136/BJSPORTS-2018-099991. https://doi.org/10.1136/BJSPORTS-2018-099991 - DOI - DOI - PMC - PubMed
-
- Incidence of midportion Achilles tendinopathy in the general population. De Jonge S., Van Den Berg C., De Vos R. J.., et al. 2011Br J Sports Med. 45(13):1026–1028. doi: 10.1136/BJSPORTS-2011-090342. https://doi.org/10.1136/BJSPORTS-2011-090342 - DOI - DOI - PubMed
-
- Investigating achilles and patellar tendinopathy prevalence in elite athletics. Janssen I., van der Worp H., Hensing S., Zwerver J. 2018Res Sports Med. 26(1):1–12. doi: 10.1080/15438627.2017.1393748. https://doi.org/10.1080/15438627.2017.1393748 - DOI - DOI - PubMed
-
- Beyond the tendon: Experiences and perceptions of people with persistent Achilles tendinopathy. Mc Auliffe S., Synott A., Casey H., Mc Creesh K., Purtill H., O’Sullivan K. 2017Musculoskelet Sci Pract. 29:108–114. doi: 10.1016/J.MSKSP.2017.03.009. https://doi.org/10.1016/J.MSKSP.2017.03.009 - DOI - DOI - PubMed
-
- Impact of chronic Achilles tendinopathy on health-related quality of life, work performance, healthcare utilisation and costs. Sleeswijk Visser T. S. O., Van Der Vlist A. C., Van Oosterom R. F., Van Veldhoven P., Verhaar J. A. N., De Vos R. J. 2021BMJ Open Sport Exerc Med. 7(1):e001023. doi: 10.1136/BMJSEM-2020-001023. https://doi.org/10.1136/BMJSEM-2020-001023 - DOI - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous